(Q40426465)

20 September 2017

1 reference

title

Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients (English)

1 reference

20 September 2017

C L Abad

1

1 reference

20 September 2017

R R Razonable

series ordinal

2

1 reference

20 September 2017

publication date

2 December 2016

1 reference

Expert Review of Anti-infective Therapy

20 September 2017

published in

1 reference

20 September 2017

volume

15

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

93-110

1 reference

Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Herpes simplex and varicella zoster viruses: forgotten but not gone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Herpes simplex virus type 2 in the United States, 1976 to 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Herpes simplex virus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Prospective Study of Prevalence, Incidence, and Source of Herpesvirus Infections in Patients with Renal Allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Management of viral infections in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Acyclovir resistance in herpes simplex encephalitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

A retrospective, case-control study of acyclovir resistance in herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Herpes zoster after liver transplantation: incidence, risk factors, and complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Herpes zoster infection after liver transplantation: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Cytomegalovirus (CMV) in the Compromised Host(s)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Human herpesviruses 6, 7 and 8 in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Colitis in a renal transplant patient with human herpesvirus-6 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Encephalitis owing to human herpesvirus-6 after cardiac transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

A report of human herpesvirus 6-associated encephalitis in a solid organ transplant recipient and a review of previously published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Chromosomally integrated human herpesvirus-6 in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Chromosomally integrated human herpesvirus-6 in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Chromosomally integrated human herpesvirus 6: questions and answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Human herpesvirus 7 primary infection in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Ganciclovir-resistant human herpesvirus-6 encephalitis in a liver transplant patient: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Prophylaxis against herpesvirus infections in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Antiviral drugs for viruses other than human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Mechanism of action and selectivity of acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

A randomized double-blind placebo controlled trial of oral acyclovir in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Antivirals for the treatment of herpesvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Crystal-induced acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Acyclovir- and ganciclovir-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Varicella zoster virus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

The clinical pharmacokinetics of famciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

A review of famciclovir in the management of genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Safety of famciclovir in patients with herpes zoster and genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Human pharmacokinetics of the antiviral drug DHPG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Recent advances in the therapy and prevention of CMV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Ganciclovir. An update of its therapeutic use in cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Ganciclovir-resistant cytomegalovirus in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Foscarnet and crystals in glomerular capillary lumens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Neurologic sequelae associated with foscarnet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Iritis associated with intravenous cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Maribavir: a novel antiviral agent with activity against cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Design and development of oral drugs for the prophylaxis and treatment of smallpox infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Anti-BK virus activity of nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Helicase-primase inhibitor pritelivir for HSV-2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

ASP2151 for the Treatment of Genital Herpes: A Randomized, Double-Blind, Placebo- and Valacyclovir-Controlled, Dose-Finding Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

Incidence and Clinical Characteristics of Herpes Zoster After Lung Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1266253

10.1080/14787210.2017.1266253

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference